摘要
背景:阿尔茨海默病(AD)的早期阶段是在与学习和记忆相关的脑区内微调神经元电路的中断。这种调整是从调节皮层网络功能的兴奋性和抑制性输入的微妙的平衡中获得的。这种稳态可塑性大脑中相应的信息传递的动态提供了依据。兴奋性突触传递的主要是由谷氨酸能突触而抑制突触传递涉及GABA能和甘氨酸信号驱动。 GABA能细胞,负责在成人大脑抑制传输,最近已成为AD研究的重点。GABA能中间神经元是β淀粉样蛋白的靶点,这一发现表明兴奋性/抑制平衡的异常有助于皮质调节的变化,可能与病理发展有关。因此,了解有关GABA能改变分子的细节可以更好的帮助我们了解AD的发病机制。 目的:本文回顾了最近的研究,这些研究说明了早期改变的概念,AD的抑制电路和考虑其对膜GABA成分功能,细胞和微电路的水平的影响。 结论:基于AD的GABA能细胞和对微电路的特殊兴趣,这些方法可能会导致新的假设,动物模型和治疗策略。
关键词: β-淀粉样蛋白,GABA能中间神经元,远程投射神经元,神经回路,突触传递
Current Alzheimer Research
Title:GABAergic Microcircuits in Alzheimer's Disease Models
Volume: 14 Issue: 1
Author(s): Vincent Villette and Patrick Dutar
Affiliation:
关键词: β-淀粉样蛋白,GABA能中间神经元,远程投射神经元,神经回路,突触传递
摘要: Background: The early phase of Alzheimer's disease (AD) involves the disruption of finely tuned neuronal circuitry in brain regions associated with learning and memory. This tuning is obtained from the delicate balance of excitatory and inhibitory inputs which regulate cortical network function. This homeostatic plasticity provides a dynamic basis for appropriate information transfer in the brain. Excitatory synaptic transmission is driven mainly by glutamatergic synapses whereas inhibitory synaptic transmission involves GABAergic and glycinergic signaling.
GABAergic cells, responsible for inhibitory transmission in adult brain, have recently become the subject of study in AD research. The discovery that GABAergic interneurons are targets of the amyloid-beta (Aβ) peptide suggest that deregulation of the excitatory/inhibitory balance contributes to changes in cortical regulation, possibly with consequences for the development of the pathology. Thus, understanding the molecular details involved in GABAergic alterations may provide insight into the pathogenesis of AD. Objective: Here, we review recent discoveries illustrating the concept of early alterations to the inhibitory circuits in AD and consider their functional implications for GABAergic components at membrane, cellular and microcircuit levels. Conclusion: We look at approaches that may lead to new hypotheses, animal models and therapeutic strategies based on GABAergic cells in AD with particular interest in microcircuits.Export Options
About this article
Cite this article as:
Vincent Villette and Patrick Dutar , GABAergic Microcircuits in Alzheimer's Disease Models, Current Alzheimer Research 2017; 14 (1) . https://dx.doi.org/10.2174/1567205013666160819125757
DOI https://dx.doi.org/10.2174/1567205013666160819125757 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Selective Serotonin Re-Uptake Inhibitors and Hyponatremia in Acutely Medically-Ill Inpatients
Current Drug Safety Molecular Mechanisms Involved in the Aging of the T-cell Immune Response
Current Genomics Depression, Serotonin and Tryptophan
Current Pharmaceutical Design Currently Available Drugs for the Treatment of Obesity: Sibutramine and Orlistat
Mini-Reviews in Medicinal Chemistry Progress in the Discovery of BACE Inhibitors
Current Pharmaceutical Design Biochemical Differentiation of Cholinesterases from Normal and Alzheimers Disease Cortex
Current Alzheimer Research Structure – Function Relationships of Pre-Fibrillar Protein Assemblies in Alzheimers Disease and Related Disorders
Current Alzheimer Research Liver X Receptor-Mediated Gene Regulation and Cholesterol Homeostasis in Brain: Relevance to Alzheimers Disease Therapeutics
Current Alzheimer Research Heart Failure Pharmacotherapy and Supports in the Elderly - A Short Review
Current Cardiology Reviews Catechol-O-methyltransferase, Cognition and Alzheimer's Disease
Current Alzheimer Research The Role of VE-cadherin in Blood-brain Barrier Integrity Under Central Nervous System Pathological Conditions
Current Neuropharmacology Mitochondrial Tolerance to Drugs and Toxic Agents in Ageing and Disease
Current Drug Targets Stress, Depression, Resilience and Ageing: A Role for the LPA-LPA1 Pathway
Current Neuropharmacology The Pursuit of Differentiated Ligands for the Glucocorticoid Receptor
Current Topics in Medicinal Chemistry Promising Anti-stroke Signature of Voglibose: Investigation through In- Silico Molecular Docking and Virtual Screening in In-Vivo Animal Studies
Current Gene Therapy Agonism of Peroxisome Proliferator Receptor-Gamma may have Therapeutic Potential for Neuroinflammation and Parkinsons Disease
Current Neuropharmacology Alzheimers Disease Drug Development in 2008 and Beyond: Problems and Opportunities
Current Alzheimer Research Metal Protein Attenuating Compounds (MPACs): An Emerging Approach for the Treatment of Neurodegenerative Disorders
Current Bioactive Compounds Hypothyroidism and Endothelial Function: A Marker of Early Atherosclerosis?
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Editorial [Hot Topic: Innate Immune Responses in CNS Neurodegenerative Diseases (Guest Editors: Hans van Noort and Sandra Amor)]
CNS & Neurological Disorders - Drug Targets